Anlon Healthcare Ltd (MAINBOARD)

IPO Details

Key Performance Indicator (KPI)

Company Financial ( In ₹ Crore)

Peer Comparison (Valuation)

About Company

• Established in 2013, Anlon Healthcare Limited is engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs).
• Products are widely used in medicines, nutraceuticals, personal care, and veterinary health.

Product Standards & Compliance:

• Manufacturing is carried out in line with Indian and international pharmacopeia standards including IP, BP, EP, JP, and USP.
• Focus on high-purity outputs, with processes designed to minimize impurities.

Custom Manufacturing Capabilities:

• Offers custom chemical manufacturing services for complex requirements.
• Provides solutions tailored to meet specific purity and formulation needs of global customers.

Regulatory Approvals & Filings:

• Received Drug Master File (DMF) approvals from ANVISA (Brazil), NMPA (China), and PMDA (Japan) for Loxoprofen Sodium Dihydrate and Loxoprofen Acid APIs.
• Filed 21 DMFs with various global authorities.
• Currently preparing filings for Ketoprofen and Dexketoprofen Trometamol approvals.

Product Portfolio:

• 65 commercialized products.
• 28 products at the pilot stage.
• 49 products under laboratory testing.

Quality & R&D:

• Quality is ensured through rigorous testing, analysis, and continuous process improvements.
• Supported by 4 advanced laboratories.
• Backed by a 34-member technical team, including 24 science graduates, ensuring strong R&D and quality compliance.

Strength

Strong Promoters & Experienced Management: Led by dedicated promoters and a skilled management team, driving strategies, innovation, diversification, and customer-focused growth since inception.

High Entry & Exit Barriers: Long customer approval cycles and strict domestic & international standards create strong entry barriers, ensuring consistent demand and limited competition.

Robust In-House Quality Control: Backed by four advanced testing labs, the company ensures rigorous quality checks, process optimization, and compliance with customer and industry standards.

Weakness

Stringent Quality Compliance: Failure to meet strict technical specifications, inspections, and audits may lead to order cancellations, warranty claims, and loss of business.

Customer Concentration Risk: Revenue depends on a limited number of customers; losing any major client could significantly impact financial performance and cash flows.

Dependency on Pharma Industry Demand: Major revenue comes from pharma sector sales; reduced demand or new alternate drugs could adversely affect business growth and profitability.